Resverlogix Corp
XMUN:RFS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Resverlogix Corp
XMUN:RFS
|
CA |
|
M
|
Macy's Inc
F:FDO
|
US |
|
Oyo Corp
TSE:9755
|
JP |
|
M
|
MTI Investment SE
STO:MTI
|
SE |
|
Union Insurance Co Ltd
TWSE:2816
|
TW |
|
D
|
Dorsel Holdings Ltd
TASE:DRSH
|
IL |
|
Sergeferrari Group SA
PAR:SEFER
|
FR |
|
Cambium Networks Corp
OTC:CMBMF
|
US |
|
F
|
FedEx Corp
SWB:FDX
|
US |
|
F
|
First Mining Gold Corp
OTC:FFMGF
|
CA |
|
S
|
Samji Electronics Co Ltd
KOSDAQ:037460
|
KR |
|
N
|
Network-1 Technologies Inc
AMEX:NTIP
|
US |
|
TotalEnergies SE
PAR:TTE
|
FR |
Resverlogix Corp
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
